Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Quote. Delayed Australian Stock Exchange - 01/20 07:43:43 pm
0.39 AUD   -1.27%
01/03Hexima Appoints Commercial Chief
MT
01/03Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
CI
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 for the Treatment of Onychomycosis at American Podiatric Medical Association Annual Conference

04/25/2021 | 08:53pm EST

Hexima Limited announced that it has been selected to present clinical data from its Phase I/IIa clinical trial of HXP 124 for the treatment of onychomycosis at the annual meeting of the American Podiatric Medical Association (APMA) in Aurora, Colorado in July 2021. The APMA represents an important venue for the presentation of HXP124's potential in onychomycosis. Podiatrists are the specialists who tend to manage most cases of onychomycosis and importantly write 80% of all prescriptions for onychomycosis in the US. Onychomycosis is a common fungal nail infection in the nail plate and nail bed. Prevalence of onychomycosis has been estimated at between 10% (Japan) and 13.8% (USA). Onychomycosis is an infectious disease with significant healthcare burden, it causes pain in approximately 50% of patients and in the US results in close to four doctor's visits annually for treatment.[3] Onychomycosis impacts a patient's quality of life with 51% unable to wear the shoes they would prefer and 66% distressed by the appearance of their nail. It is important to treat onychomycosis as the fungi in the nail and can be a source of secondary infection in other areas of the body or infect family members and spread to the environment. Onychomycosis is the most common nail disorder, and the most common skin infection, accounting for 50% of all nail diseases. It is particularly prevalent in older, diabetic and immune compromised populations. The global market for treatments for onychomycosis was approximately USD 3.7 billion in 2018. Approved prescription therapies for onychomycosis comprise either oral or topical medications. Oral medications are associated with adverse effects such as nausea, taste disturbance, and flatulence. They can also severely impact liver function and so often require liver function monitoring. The clinical and commercial success of topical medications has been constrained by an inability of anti-fungal agents to effectively penetrate the human nail and the lack of sufficient anti-fungal activity when in contact with the target pathogen.


ę S&P Capital IQ 2021
All news about HEXIMA LIMITED
01/03Hexima Appoints Commercial Chief
MT
01/03Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
CI
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
2021Hexima Names New Chief Development Officer
MT
2021HEXIMA : CEO's Presentation
PU
2021Hexima Limited Announces Cessation of Marilyn Anderson as Executive Director
CI
2021Hexima Limited Announces Appointment of Shari Lipner as Member of its Scientific Adviso..
CI
2021Hexima Limited Announces Appointment of Nancy Sacco as Chief Development Officer
CI
2021Hexima Completes Oversubscribed Share Purchase Plan
MT
More news
Financials
Sales 2022 - - -
Net income 2022 -9,30 M -6,68 M -6,68 M
Net cash 2022 41,5 M 29,8 M 29,8 M
P/E ratio 2022 -6,69x
Yield 2022 -
Capitalization 64,4 M 46,4 M 46,3 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees -
Free-Float 69,6%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,39 AUD
Average target price 0,75 AUD
Spread / Average Target 92,3%
EPS Revisions
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED-6.02%46
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508